TFXTeleflex exhibits solid fundamental strengths with consistent earnings and a manageable debt load. However, recent performance has been weak, and valuation metrics suggest it may be fairly valued or slightly overvalued. Technical indicators point to a neutral to slightly bearish short-term outlook. The company operates in a stable, but not high-growth, sector.
Teleflex operates in the medical devices sector, which benefits from an aging global population and increasing healthcare spending. However, it faces intense competition and potential regulatory headwinds. Its focus on critical care and surgical applications provides a stable demand base.
Teleflex demonstrates robust profitability and a solid balance sheet. Revenue growth has been stable, and earnings have consistently met or exceeded expectations. The company's net profit margin is healthy, supported by efficient operations.
The stock is trading significantly below its 52-week high and has experienced a substantial decline over the past year. While there are some short-term indicators suggesting potential stabilization, the overall trend is bearish. Moving averages and momentum indicators signal caution.
| Factor | Score |
|---|---|
| Healthcare Spending Growth | 75 |
| Medical Device Innovation | 60 |
| Regulatory Environment | 40 |
| Competitive Landscape | 50 |
| Aging Population Tailwinds | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 65 |
| Growth | 30 |
| Balance Sheet Health | 85 |
| Cash Flow | 90 |
| Earnings Consistency | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 40 |
| Short-Term Oscillators | 35 |
Consistent EPS Beat
The company has exceeded earnings per share (EPS) estimates for the last 8 consecutive quarters, demonstrating consistent operational execution and profitability.
Undervalued Relative to Peers
With a P/E ratio of 35.97, the stock appears relatively undervalued compared to its industry peers, suggesting potential for price appreciation.
High P/E Ratio
The current P/E ratio of 35.97 is significantly higher than the historical average and industry benchmarks, potentially indicating overvaluation and a risk of price correction.
Slowing Revenue Growth
Revenue for the latest reported period (2024Q4) shows a decline of 17.2% year-over-year, indicating a significant slowdown in top-line growth.
May 2025
20
Ex-Dividend Date
June 2025
16
Next Dividend Date
July 2025
31
Next Earnings Date
H: $3.42
A: $3.37
L: $3.24
H: 775.00M
A: 771.53M
L: 759.30M
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
149.62 USD
The 39 analysts offering 1 year price forecasts for TFX have a max estimate of 200.00 and a min estimate of 123.00.